All In Biotech

Drug Trial Radar · NCT00547378

InSite for Over Active Bladder

Prospective, Multicenter Trial Evaluating the Safety and Efficacy of InterStim® Therapy in Subjects With Symptoms of Overactive Bladder (InSite OAB)

Last checked: Nov 20, 2026Latest source record: Dec 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 571 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

571

Actual

Start

Oct 2007

Primary completion

Aug 2016

Study completion Aug 2016

Sponsor

Lead sponsor
MedtronicNeuroIndustry
Sponsor type
Industry
First posted
Oct 22, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purposes of this study are: 1. To provide evidence from a randomized controlled trial that InterStim Therapy provides better relief of symptoms of OAB than standard medical treatments in current use. 2. To fulfill the requirements of the FDA-mandated post-approval study of the safety of the tined lead using a minimally invasive approach.

Conditions

  • Urinary Incontinence, Urgency-frequency
  • Overactive Bladder

Interventions

  • InterStimDevice

  • Standard Medical TherapyDrug

    Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Randomized Cohort: OAB Therapeutic ResponseTime frame: 6 months
  2. All Implanted Cohort: Adverse Events Related to the Tined Lead That Require SurgeryTime frame: 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.